Summary: VEGF and bFGF expression and tumor microvessel density in tumor lesions were analyzed in 70 patients with maxillary sinus squamous cell carcinoma. The VEGF expression dependent of p53 overexpression and/or mutations was associated with angiogenesis, decreased spontaneous tumor apoptosis and metastases, while the bFGF expression was associated with resistance to radiochemotherapy, resulting in poor prognosis.
Introduction
Angiogenesis, the formation of new capillaries out of pre-existing vessels, plays a crucial role in solid tumor growth [1, 2] and facilitates tumor progression and metastasis [3, 4] . Angiogenesis is regulated by a large number of angiogenic factors, including vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). Although tumor-derived bFGF has both autocrine and paracrine functions, VEGF is produced only by tumors for the stimulation of tumor vascularization. VEGF is a disulfide-linked dimeric glycoprotein that increases blood vessel permeability and promotes endothelial cell growth, proliferation, migration and differentiation [5] . bFGF is involved in proliferation and differentiation of a wide range of cell types and exhibits a potent angiogenic activity [1] .
In head and neck squamous cell carcinoma (SCC), a number of reports have been documented VEGF expression [6] [7] [8] [9] [10] [11] [12] [13] , bFGF expression [14-16] and tumor microvessel density [11, 12, [17] [18] [19] [20] [21] [22] [23] . Some reports showed that expression of VEGF [11, 24] and bFGF [25] was associated with an increase in the tumor microvessel density. However, conflicting results have been presented with regard to the correlation of VEGF and bFGF expression with disease prognosis or tumor growth. Some studies have demonstrated that there is a significant correlation of VEGF and bFGF expression with poorer prognoses [6, 10, [12] [13] [14] [15] whereas others have shown no correlation [7] [8] [9] 11, 16] . On the other hand, many other studies have demonstrated a close association of tumor microvessel density with poorer prognoses [12, 17, 18, [21] [22] [23] although a few have shown no association [11, 19] . In general, 5, Bandoh 5 these studies of head and neck SCC lesions have lumped together tumors with different anatomic sites within the head and neck, with the exception of certain studies on laryngeal SCC patients [9, 11, 22] . Since variations in clinical and/or etiological behaviors may exist between different sites in the head and neck SCC, analysis from a single anatomic site is warranted. However, this has not been fully studied in maxillary sinus SCC as of yet.
Previously, we showed that p53 mutations, loss of bax expression, decreased spontaneous tumor apoptosis or low histological effectiveness of radiochemotherapy were significantly correlated with poorer prognoses in maxillary sinus SCC [26] . Furthermore, we found that bax expression was associated with increased spontaneous tumor apoptosis, while decreased spontaneous tumor apoptosis and p53 mutations correlated with low histological effectiveness of radiochemotherapy, suggesting that higher levels of spontaneous tumor apoptosis induced by bax expression may increase the sensitivity of tumors to radiochemotherapy, thereby resulting in good prognoses, while p53 mutations may lead to resistance against radiochemotherapy, resulting in poor prognoses. Recently, it has been reported that VEGF expression correlates with p53 overexpression and/or mutations in noninvasive colorectal carcinoma [27] , lung carcinoma [28] , primary breast carcinoma [29] and head and neck SCC [16] . It is also reported that VEGF expression and/or high tumor microvessel density correlate with lower levels of tumor apoptosis in gastric carcinomas [30] [31] [32] , esophageal SCC [33] and head and neck SCC [34] . A recent in vitro study showed that bFGF expression was associated with resistance to 6, Bandoh 6 chemotherapeutic agents in a human bladder cancer cell line [35] .
The present study is the first attempt to examine the VEGF and bFGF expression and tumor microvessel density using immunohistological methods, and to investigate correlations of these angiogenic factors with p53 status, tumor apoptosis, the effectiveness of radiochemotherapy and disease prognosis in maxillary sinus SCC patients.
Patients and methods

Patient characteristics
The study group consisted of 70 Japanese patients (49 males and 21 females; age range: 36-86, median age: 67) who were treated for maxillary sinus SCC in the Department of Otolaryngology-Head and Neck Surgery, Asahikawa Medical College, between 1980 and 2000. All patients signed informed consents for therapy and tissue studies, which had received prior approval from the Institutional Review Board. This group had been previously studied for expression of apoptosis-related proteins including p53, Fas, bax and bcl-x L as well as spontaneous tumor apoptosis and mutation in the p53 gene in relation to disease prognosis [26] .
Clinical features, expression of apoptosis-related proteins and the p53 gene status of the patients are listed in Table 1 [26] . According to the 1997 UICC TNM staging systems (identical to 1997 AJCC classification); T1 was not seen, T2 was present in 8 patients Of 70 patients, 57 patients were treated with preoperative radiochemotherapy followed by total or partial maxillectomy. The preoperative radiochemotherapy including local irradiation with a total dose of 50 Gy (2.5 Gy x 20 fractions, 5 days a week) along with concomitant intra-maxillary arterial infusion of 5-fluorouracil (5FU) at a total dose of 5000 mg (250 mg x 20 times) [36] . After the treatment, 9 patients developed neck lymph node and/or distant metastases. The remaining 13 patients were treated with radiotherapy alone because of inoperable intracranial invasion, advanced age with poor performance status, refusal of surgery, or comorbidities. Follow-up period of all patients ranged from 2 to 189 months with a median of 61 months. The 5-year overall and cause-specific survival rates for all patients were 48.5% and 75.7%, respectively; for 13 patients who received 8, Bandoh radiotherapy alone, these rates were 13.1% and 0%, respectively. For 57 patients who underwent preoperative radiochemotherapy followed by total or partial maxillectomy, the follow-up period ranged from 2 to 189 months with a median of 65 months (89 months for surviving patients). Of these 57 patients, 24 (42%) patients had died during follow-up, including 8 (14%) of tumor-related death and 16 (28%) of death from comorbidities. The 5-year overall and cause-specific survival rates were 55.6% and 81.2%, respectively [26] .
We have examined histological effectiveness of radiochemotherapy in surgically resected specimens obtained from 57 patients treated with radiochemotherapy followed by maxillectomy [26] . Histological effectiveness was classified into 5 grades according to the evaluation system proposed by Shimosato et al. [37] 2 ). Then, slides were scanned at low power magnification (x100). In each tumor, "hot spot" areas displaying the highest vessel density were selected, as described previously [4] . The maximum vessel density (MVD) was determined from these "hot spot" areas at fields under high power magnification (x200, 0.94mm 2 ). Sections stained with anti-mouse IgG1 mAb were used as negative controls.
Statistical analysis
Two group comparisons were tested using the Mann-Whitney U test and Fisher's exact test and summarized with their appropriate p-values. Cause-specific survival time was measured from the date of surgical removal of tumor to the date of death due to the original disease or final visit. The probability of the cause-specific survival was calculated using the Kaplan-Meier method and compared using the log-rank test.
Results
VEGF and bFGF expression and tumor microvessel density
VEGF was expressed in 35 (50%) of 70 patients and bFGF was in 43 (61%) ( 3.2. VEGF and bFGF expression and tumor microvessel density in relation to p53 status
As described in our previous report [26] , 39 (56%) of 70 patients showed p53 overexpression and 20 (29%) had mutation of the p53 gene. Forty-three (61%) showed abnormal p53 status, i.e., p53 overexpression and/or mutation. VEGF expression was observed significantly more frequently in patients with abnormal p53 status than in those with normal p53 status (61% vs. 33%; p=0.048; Table 2 ). The bFGF tended to be expressed more frequently in the patients with abnormal p53 status than in those with normal p53 status (74% vs. 51%; p=0.082). (28%). Neither Grade 0 nor Grade I was identified [26] . As shown in Table 3 Kaplan-Meier analysis showed that cause-specific survival was significantly worse in patients with high MVD (≥80) than in those with low MVD (<80) (p=0.042; Fig. 6 ).
Kaplan-Meier analysis showed that cause-specific survival was significantly worse in patients with high MVD (≥80) than in those with low MVD (<80) (p=0.042; Fig. 6 ). The VEGF and bFGF expression did not significantly correlate with either metastases or causespecific survival.
Discussion
Angiogenesis, which is regulated by a number of angiogenic factors, plays a crucial role in solid tumor growth [1, 2] and facilitates tumor progression and metastasis [3, 4] . Among angiogenic factors, VEGF is generally regarded as the most potent factor and 14, Bandoh 14 the most likely candidate for the induction of tumor growth, because it is a soluble secreted endothelial cell mitogen and its receptor such as kinase insert domain containing receptor (KDR) is selectively expressed by activated endothelium [38, 39] . Angiogenesis can be monitored in a variety of ways including the tumor microvessel density. Some reports showed that VEGF expression correlated with increased tumor microvessel density in head and neck SCC [24] and laryngeal SCC [11] . Our study also showed that VEGF expression was closely associated with angiogenesis assisted by tumor microvessel density in maxillary sinus SCC.
It has been reported that VEGF expression correlated with p53 overexpression in noninvasive colorectal [27] , lung [28] and primary breast carcinoma [29] . In head and neck SCC, Riedel et al.
[16] demonstrated a significant correlation between p53 mutation and VEGF expression. Our present study clearly showed that abnormal p53 status, i.e., p53 overexpression and/or p53 gene mutation, was closely associated with VEGF expression in maxillary sinus SCC. These findings suggest that VEGF expression may be at least partly regulated by the p53 gene function. The hypothesis is supported by several lines of in vitro data [40] [41] [42] . Kieser et al. [40] demonstrated that mutant p53 could enhance VEGF expression induced by tumor promoting phorbol esters, such as 12-O-tetradecanoylphorbol-13-acetate, via activation of protein kinase C. Mukhopadhyay et al. [41] showed that wild-type p53 represses v-Src-mediated VEGF upregulation. Recently, Bouvet et al. [42] showed that transduction of p53-negative colon carcinoma cells with an 15, Bandoh adenoviral vector encoding wild-type p53 can decrease tumor growth by inhibiting VEGF mRNA expression.
It was reported in both in vivo and in vitro studies that angiogenic inhibition induces and sustains the dormancy of experimental tumors and micrometastases by increasing apoptotic cell death in tumor cells [43, 44] . In surgically resected tumor tissues of gastric carcinomas [30] [31] [32] and esophageal SCC [33] , VEGF expression and/or a high tumor microvessel density were reported to correlate with lower levels of apoptosis. In head and neck SCC, Riedel et al. [34] recently showed that high tumor vascularity correlated with low expression of pro-apoptotic factors such as FasL and caspase-3. In the present series of maxillary sinus SCC, we found that VEGF expression and higher tumor microvessel density were associated with lower levels of spontaneous tumor apoptosis.
These data suggest that an inverse correlation between angiogenesis and apoptosis may exist in some malignancies including maxillary sinus SCC. This may be explainable by the close association between VEGF expression and abnormal p53 status, since VEGF induces angiogenesis and p53 mutation inhibits apoptosis. Hypoxia may be a link between apoptosis and angiogenesis. Hypoxia is a potent inducer of wild type p53 activity [45] and a strong relationship has been found between wild type p53 activity and stress-induced apoptosis [46] . Hypoxia may also induce anti-angiogenic regulators such as thrombospondin, presumably through the activity of p53 [47] . Alternatively, the inverse correlation between angiogenesis and apoptosis may be explainable by the anti-apoptotic 16, Bandoh function of VEGF by induction of bcl-2 expression, activation of the mitogen-activated protein kinase (MAPK) and inhibition of c-jun-N-terminal-kinase (JNK) [48, 49] .
Correlation between VEGF expression and bcl-x L expression observed here may support this possibility.
Although some conflicting results were reported [11, 19] , the majority of the reports in head and neck SCC showed that high tumor microvessel density correlated with tumor progression, recurrence, and/or poor prognosis [12, 17, 18, [21] [22] [23] . The presence of high tumor microvessel density was reported to be useful as a predictor of metastases and/or poorer prognoses [17, 22, 23] . In our series of maxillary sinus SCC, high tumor microvessel density was significantly associated with neck lymph node and/or distant metastases as well as poorer prognoses.
There are some reports which indicate that bFGF expression correlated with tumor growth and metastasis in head and neck SCC [14, 15] , but no correlation is also reported [16] . In the present series of maxillary sinus SCC, we found a significant correlation between bFGF expression and low effectiveness of radiochemotherapy. A recent in vitro study showed that bFGF expression as a result of transfection markedly suppresses the cisplatin-induced apoptosis in a human bladder cancer cell line, suggesting that bFGF expression may lead to resistance to chemotherapeutic agents [35] . The persistence of the disease after radiochemotherapy is usually a poor prognostic factor, since it is frequently associated with a higher risk of distant metastases and a worse prognosis [50] . Indeed, we 17, Bandoh have already found that the presence of tumor cells in surgically resected tissues after radiochemotherapy was closely related to poor disease-free survival in the same patients as those described in the present study [26] . Expression of bFGF is reported to be inhibited by p53 post-transcriptionally in human skin fibroblasts [51] . In this study, we showed that high bFGF expression tended to be associated with abnormal p53 status. It is indicated, on the basis of these data, that high bFGF expression, which is caused in part by abnormal p53 status, may be associated with poor prognosis via its resistant effect to radiochemotherapy in maxillary sinus SCC.
Some studies, in head and neck SCC other than maxillary sinus SCC, showed that VEGF expression correlated with tumor aggressiveness and/or poor prognosis [6, 10, 12, 13 ].
In contrast, other studies showed no correlation of VEGF expression with tumor size, lymph node status, and/or prognosis [7] [8] [9] 11] . These differences are likely to be caused by the different methods to assess VEGF expression and by lumping together tumors with different sites in head and neck lesion. In the present study of maxillary sinus SCC patients, VEGF expression did not directly correlate with the clinical outcome, but was significantly correlated with high tumor microvessel density, which is a significant indicator of poorer prognoses. Therefore, VEGF expression may be associated with poorer prognoses via the ability of VEGF to induce increased tumor microvascularity in maxillary sinus SCC lesions.
In combination with our previous study [26] , we conclude that p53 mutations, 18, Bandoh decreased spontaneous tumor apoptosis and high tumor microvessel density may be useful prognostic factor for predicting long-term outcomes in maxillary sinus SCC patients.
VEGF expression in association with abnormal p53 status may lead to increased tumor microvascularity and decreased tumor apoptosis, while bFGF expression may lead to resistance against radiochemotherapy. Because these molecular events contribute to poorer prognoses, they may also serve as candidate therapeutic targets in anti-cancer strategies.
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